Tornier N.V. Rallies on Alleged Johnson & Johnson Takeover (TRNX)

Tornier N.V

, a company that shares some of the orthopedic, neurological, spine, and trauma market space as Johnson & Johnson

, rallied over 5% yesterday on rumors of a possible takeover. The year-to-date performance of Tornier has rewarded shareholders with over 16% return in 2011. In addition to the shared market space of the two companies, additional speculation circulated that the Synthes deal could be an attractive business component for Johnson & Johnson via a synergy with Tornier N.V.'s additional medical expertise and market presence. As a reminder, Johnson & Johnson and Synthes announced early on Wednesday morning that the two companies had

for Johnson & Johnson to buy the Swiss company for 159 Swiss francs per share, or a total of US$21.3 billion at then-current exchange rates. Johnson & Johnson and Synthes said that together they would be better able to address market trends that include an aging population, growing demand in emerging markets and more patients with joint diseases caused by increasing obesity rates. Speculators are wondering whether Tornier N.V. might be able to complement this acquisition in the orthopedic, neurological, spine, and trauma market space. Additional information about Johnson & Johnson can be found

. At the moment, this speculation is unconfirmed. If the Johnson & Johnson's acquisition of Synthes, Inc leads to more deals in the medical device sector, other companies like Medtronic Inc.

, Boston Scientific Corporation

and Thermo Fisher Scientific, Inc.

could see their share prices climb higher. Investors who want exposure to this sector but would prefer a more diversified investment might take a look at the iShares Dow Jones U.S. Medical Device

ETF. This article may include mentions of rumors, chatter, or unconfirmed information. Readers should beware that while unconfirmed information may be correlated with increased volatility in securities, price movements based on unofficial information may change quickly based on increased speculation, clarification, or release of official news. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.